ClinicalTrials.gg
RecruitingNCT07615829Updated Jul 6, 2026

Health Benefits of Dance Exercise

An interventional study of Exercise training and No exercise training in Metabolic Health, Mental Health and Physical Performance, sponsored by University of Thessaly. Recruiting at 1 site in Greece. Open to female participants aged 35 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-06.

Sponsored by University of Thessaly · Not applicable, Interventional, and Other

From the registry’s dates

  • Started May 2026; still recruiting 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
35 Years to 70 Years
Sex
Female
01

Study summary

In Greece, people of different age groups, including young children to older adults, participate in dance exercise training. Although it is well-known that regular participation in dancing is associated with benefits such as entertainment, socialization and increased physical activity, the long-term effects of dancing on metabolic and mental health as well as physical performance remain largely unknown. Therefore, the aim of this study is to investigate the effects of a 6-month dancing exercise intervention on metabolic and mental health and physical performance in premenopausal and postmenopausal women.

Read the detailed description

Twenty premenopausal and twenty postmenopausal inactive women meeting the inclusion criteria will be randomly assigned to a Control (n=20) or an Experimental group (n=20). The Control group will maintain their habitual physical activity level without participating in any form of exercise training. The Experimental group will participate in two weekly dance exercise training sessions over a 6-month period. Each session will be performed under supervision and include a 10-min warm up (2-3 dances of very slow tempo), a 45-min main dance exercise session (\~15 dances of various tempos i.e. slow, moderate and fast tempo) and a 5-min cool-down period (walking and stretching). Heart rate will be continuously monitored during each session by using heart rate monitors while the rate of perceived exertion (RPE) will be recorded at the end of each session. In addition, prior to the second dance exercise session in each week, participants' delayed onset of muscle soreness (DOMS) and wellness status (through the wellness report) will be evaluated. Prior to (Baseline) and after the intervention period (at 6 months) participants of both groups (Control and Experimental) will undergo resting blood sampling and assessment of their (i) anthropometrics, (ii) body composition, (iii) physical performance, (iv) physical activity level, (v) dietary intake, (vi) quality of life and (vii) mental health.

02

Conditions studied

  • Metabolic Health
  • Mental Health
  • Physical Performance
03

In context

Psychological Well-Being

2,195 studies on the registry are indexed under Psychological Well-Being; 728 are open to participants now.

This study's planned enrollment of 40 is below the median of 110 across 1,798 interventional studies indexed under Psychological Well-Being.

Browse Psychological Well-Being studies →

Lead sponsor

University of Thessaly is the lead sponsor of 195 studies on the registry; 44 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
35 Years to 70 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Free of musculoskeletal injuries
  • Free of chronic non-communicable diseases
  • Normal menstrual cycle (for premenopausal women)
  • No recent childbirth (previous 12 months) (for premenopausal women)
  • At least 12 months since the oncet of menopause (for women)
  • Non smokers

Exclusion criteria

Exclusion Criteria:

  • Pregnancy (for premenopausal women)
  • to exercise training
  • Illness or other medical condition
  • Use of medication
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Active comparator
    Control Group

    Participants in this group will maintain their habitual physical activity level without participating in any form of exercise training

    Other: No exercise training

  • Experimental
    Experimental Group

    Participants in this group will participate in two weekly dance exercise training sessions over a 6-month period

    Other: Exercise training

Interventions

  • OtherExercise training

    This intervention will consist of two weekly dance exercise training sessions over a 6-month period. Each session will be performed under supervision and include a 10-min warm up (2-3 dances of very slow tempo), a 45-min main dance exercise session (\~15 dances of various tempos i.e. slow, moderate and fast tempo) and a 5-min cool-down period (walking and stretching)

  • OtherNo exercise training

    It will include only habitual physical activity level without participating in any form of exercise training

06

What researchers measure

Primary outcomes

  1. Change in glucose concentration

    Fasting glucose concentration will be determined in blood

    Time frame: At baseline and 6 months

  2. Change in insulin concentration

    Fasting insulin concentration will be determined in blood

    Time frame: At baseline and 6 months

  3. Change in total cholesterol concentration

    Total cholesterol concentration will be determined in blood

    Time frame: At baseline and 6 months

  4. Change in HDL cholesterol concentration

    HDL cholesterol concentration will be determined in blood

    Time frame: At baseline and 6 months

  5. Change in LDL cholesterol concentration

    LDL cholesterol concentration will be determined in blood

    Time frame: At baseline and 6 months

  6. Change in triglycerides concentration

    Triglycerides concentration will be determined in blood

    Time frame: At baseline and 6 months

  7. Change in serum glutamic-oxaloacetic transaminase (SGOT/AST) concentration

    SGOT concentration will be determined in blood

    Time frame: At baseline and 6 months

  8. Change in alanine aminotransferase (SGPT/ALT) concentration

    SGPT concentration will be determined in blood

    Time frame: At baseline and 6 months

  9. Change in gamma-glutamyl transpeptidase (γ-GT) concentration

    γ-GT concentration will be determined in blood

    Time frame: At baseline and 6 months

  10. Change in body weight

    Time frame: At baseline and 6 months

  11. Change in waist circumference

    Time frame: At baseline and 6 months

  12. Change in hip circumference

    Time frame: At baseline and 6 months

  13. Change in fat mass

    Fat mass will be assessed using whole-body dual-energy X-ray absorptiometry (DXA)

    Time frame: At baseline and 6 months

  14. Change in body fat percentage (%)

    Body fat percentage (%) will be assessed using whole-body dual-energy X-ray absorptiometry (DXA)

    Time frame: At baseline and 6 months

  15. Change in fat free mass

    Fat free mass will be assessed using whole-body dual-energy X-ray absorptiometry (DXA)

    Time frame: At baseline and 6 months

  16. Change in lean body mass

    Lean body mass will be assessed using whole-body dual-energy X-ray absorptiometry (DXA)

    Time frame: At baseline and 6 months

  17. Change in cardiorespiratory fitness

    Cardiorespiratory fitness will be assessed using the Ebbeling single stage treadmill test

    Time frame: At baseline and 6 months

  18. Change in functional performance

    Functional performance will be assessed using the Short Physical Performance Battery

    Time frame: At baseline and 6 months

  19. Change in muscle endurance

    Muscle endurance will be assessed using the push-up and curl-up testing protocols

    Time frame: At baseline and 6 months

  20. Change in resting blood pressure

    Resting systolic and diastolic blood pressure will be assessed using a sphygmomanometer

    Time frame: At baseline and 6 months

  21. Change in quality of life

    Quality of life will be evaluated using questionnaire

    Time frame: At baseline and 6 months

  22. Change in vitality

    Vitality will be evaluated using questionnaire

    Time frame: At baseline and 6 months

  23. Change in anxiety level

    Anxiety will be evaluated using questionnaire

    Time frame: At baseline and 6 months

  24. Change in flourishing

    Flourishing will be evaluated using questionnaire

    Time frame: At baseline and 6 months

Secondary outcomes

  1. Change in dietary intake

    Dietary intake will be monitored using diet recalls

    Time frame: At baseline and 6 months

  2. Change in daily number of steps

    Daily number of steps performed will be assessed using accelerometers

    Time frame: At baseline and 6 months

  3. Change in daily time spent in moderate-to-vigorous physical activity

    The time spent in moderate-to-vigorous physical activity will be assessed using accelerometers

    Time frame: At baseline and 6 months

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2026 (actual). Primary completion is estimated for Nov 2026, 6 months after the start.

Of 1,261 non-industry interventional studies with no phase under Psychological Well-Being, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 34. This study's planned 6 months is below that.

Counting every sponsor, half of 1,304 studies reached it within 16 months; a quarter within 7 and three quarters within 34.

How these figures are worked out, and which studies are left out of them.

Registered
May 22, 2026
First posted
May 29, 2026
StartActual
May 30, 2026
Primary completionEst.
Nov 30, 2026
CompletionEst.
Dec 20, 2026
Last update
Jul 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07615829
Responsible party
Dimitrios Draganidis (Assistant Professor, University of Thessaly) — Principal investigator
First posted
May 29, 2026
Start date
May 30, 2026
Primary completion
Nov 30, 2026 (estimated)
Completion
Dec 20, 2026 (estimated)
Last update
Jul 6, 2026

Study contacts

Dimitrios Draganidis, PhD
Contact
ddraganidis@uth.gr
+30 2431047047
Ioannis G Fatouros, PhD
Contact
ifatouros@uth.gr
+ 30 2431047047
Maria Bougiesi, PhD
principal investigator · University of Thessaly, Department of Physical Education and Sport Science

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion